We at Embio believe that technology is the backbone for our success and allows us to achieve a leadership position in all the products we manufacture. With 30+ years of experience in Bacterial, Fungal & Category 1 GMO bio transformation, Embio is focused on creating fully backward integrated GMO biotransformation platforms. We believe that our pipeline of disruptive technologies will help create a first movers’ advantage, thereby creating a potential leadership position in the global market.

Licensed to manufacture Schedule-1, Schedule-2 substances, Embio is a leading global player in the domain of controlled substances, advanced intermediates and chiral molecules for more than 30 years and has demonstrated an impeccable track record in compliance and credibility in this space. Embio’s State of the Art manufacturing facility, approved by US-FDA, PMDA, KFDA, COFEPRIS & WHO-GMP, is located 175 kms from Mumbai at MIDC Mahad, on Mumbai-Goa highway.

Our products and services cater to the stringent requirements of a large clientele in more than 70+ countries with the major share in regulated markets that includes a few top 10 pharmaceutical companies in the world.

Chairman’s message

India has arrived into mainstream pharmaceutical markets around the world with many companies taking their operations worldwide. To grow and compete, Indian companies will have to re-think their current business models and move towards innovation led growth. We are focused on building a life sciences company using bio-transformation as a key technology differentiator.

That is what we are attempting to build here at Embio, using biotransformation as a key technology. The 30 plus years of journey by Embio, from its inception to its evolution, is commendable.

Embio has always leveraged its competencies to retain and grow its position of leadership in the global arena. Embio has been evolving steadily to become a global leader in the life sciences sector with its strategic focus on niche products, patented processes & products, state of the art infrastructure, disruptive technologies and empowered organizational culture. These fundamentals being in place, Embio is poised for a bright future and expected to grow exponentially.

I am confident that Embio will continue to strive to excel and make a positive difference in its growth, profitability, social responsibility as well as customer and employee satisfaction.

Mr. M. H. Avadhani

Board of Directors

Mr. M. H. Avadhani, Chairman, is a Chemical engineer and has led Embio for more than 2 and a half decades. He has extensive experience in business management with exposure to pharmaceuticals, specialty chemicals and agrochemicals industries for more than 6 decades and has been a doyen of the fertilizer industry, as Managing Director of IFFCO, KRIBHCO and as part of the founding professional team at SPIC.

Mr. M. Devesh, Managing Director, is a Pharmacy graduate from Delhi University and a M.Tech in Bio-Engineering from Andhra University. In 1997, he was selected for the Chevening Scholarship for young managers, awarded by the British Government. He started his career in the Malladi Group in projects, then R&D and as head of manufacturing operations. He started with the Company in 1995 as Vice President (Technical) and took on the role of Managing Director in 1998. He has a wide exposure to marketing, operations, finance, R&D and project management. He has been instrumental in the formulation of long term strategic plans of the company and has been a guiding force behind the growth of the company. He also plays a key role in Policy framework in the space of Narcotic Drugs and Psychotropic Substances as the Chairman of NDPS sub-committee of Indian Drug Manufacturers Association (IDMA).

Mr. R.K. Prabhu, Executive Director & CFO, is a Chartered Accountant with a degree in commerce and also in Law and has over 40 years of post-qualification experience in the Pharmaceutical and Engineering industries. He has been associated with the company for over 20 years now. Before joining Embio, he worked with two Indian multinational companies, Lupin Limited as Senior General Manager-Corporate finance for a period of 15 years, and Dodsal Limited as Executive Director for a period of one year. The sustained performance of the company is a result of the exemplary contribution of Mr. Prabhu during past 20 years.

Mr. Ajit.T. Vaswani, Independent Director , has over 60 years of experience in business and industry. Since 1981, he has served on the Boards of leading multinational companies in both executive and non-executive capacities, including as the Deputy CEO of Metal Box of India Ltd., a leading packaging company, and as the Director & Senior Vice President of Glaxo India Ltd., India’s largest and most respected pharmaceutical company. He currently serves as an Independent Director on a few Boards and chairs the Audit Committees of some of these companies.

Mr. Madhusudan G. Rao, Independent director, has an experience of 41 years in Sanofi and its legacy companies Aventis, Hoechst Marion Roussel, Hoechst India Ltd. He retired from Sanofi India Ltd in September 2014 as Senior Director, South Asia, Industrial Affairs (Technical Operations). He was board member of Sanofi India Ltd and its legacy companies for around 12 years. Post retirement, he has worked as a Technical advisor for Sanofi, India for 2years with a special focus on Shantha Biotechnics, Hyderabad which is a 100% subsidy of Sanofi, manufacturing vaccines . He was also a board member of Shantha Biotechnics between 2015 and 2017. He was Technical Advisor to Hilleman Laboratories and Virchow Biotech Pvt Ltd, Hyderabad in 2017 and 2018. Presently he has been working as a consultant to Hester Biosciences Limited, Ahmedabad and as a Board Member of Embio Limited, Mumbai.

Awards & Recognitions

Department of Biotechnology, Government of India- Biotech Product & Process Development and Commercialization Awards- 2019

MPCB 5 star rating – 2019

National safety council – Occupational Safety & Health - 2020

Get in touch